In order to further corroborate our mechanistic discovery in clinical AML patients, 24 AML patients and 16 volunteers (Table S4, Supporting Information) were enrolled to detect the expression levels of ANXA1 using immunocytochemical staining (Figures 5A and S11A, Supporting Information). This evidence concerns the gene ANXA1 and acute myeloid leukemia.